Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical market globally, with oncology as the fastest-growing therapeutic area OCALA, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has issued a patent covering the Company’s proprietary use of Ampligen® (Rintatoli ...

Core Viewpoint - Moleculin Biotech, Inc. has received a notice of allowance for a Canadian patent related to its drug candidate Annamycin, which is being developed for the treatment of hard-to-treat cancers, particularly acute myeloid leukemia and soft tissue sarcoma lung metastases [1][2][3] Group 1: Patent and Intellectual Property - The Canadian patent application covers methods for producing a preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term extending until June 2040 [2] - The company is actively building its global intellectual property portfolio for Annamycin, which includes patents in the U.S., Europe, and other major jurisdictions [3] Group 2: Drug Development and Clinical Trials - Annamycin is positioned to be the first non-cardiotoxic anthracycline approved for use, with Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML and STS lung metastases [3][4] - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML, following a successful Phase 1B/2 study [5] Group 3: Additional Pipeline and Research - In addition to Annamycin, the company is developing WP1066, an immune/transcription modulator targeting various cancers, and WP1122 for potential treatment of pathogenic viruses and certain cancer indications [6]

HOUSTON, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Houston American Energy Corp. (NYSE American: HUSA) (“HUSA” or the “Company”) and Abundia Global Impact Group (“AGIG”), today announced that production from the State Finkle Unit wells has commenced, with first revenue received. On June 17, 2024, HUSA announced plans to participate in the drilling of six wells, each with approximately three-mile laterals, on the State Finkle Unit in the Wolfcamp formation in Reeves County, Texas.  In September 2025, the Compan ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September 10, 2025. The Company believes Mr. Kane and Ms. Hemrajani add valuable expertise in finance, business development, product commercialization, and corporate strategy to its Board of Directors as the Company advances its lea ...

HOUSTON, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Houston American Energy Corp. (NYSE American: HUSA) (“HUSA” or the “Company”) and Abundia Global Impact Group (“AGIG”), today announced that production from the State Finkle Unit wells has commenced, with first revenue received. On June 17, 2024, HUSA announced plans to participate in the drilling of six wells, each with approximately three-mile laterals, on the State Finkle Unit in the Wolfcamp formation in Reeves County, Texas. In September 2025, the Compan ...

MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- NioBay Metals Inc. ("NioBay" or the "Company") (TSX-V: NBY) (OTCQB: NBYCF) is proud to announce the appointment of the first members of its Technical Advisory Committee. This committee will assist the Board of Directors and management in the next phases of the Company's development. These first members represent fields as varied as academia, geology, metallurgy, and Indigenous relations, as well as knowledge of the niobium market. We believe that the addition of ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September 10, 2025. The Company believes Mr. Kane and Ms. Hemrajani add valuable expertise in finance, business development, product commercialization, and corporate strategy to its Board of Directors as the Company advances its lea ...

Positioned for projected 50% minimum revenue growth in FY2026 following successful navigation of tariff environment Engages Forvis Mazars, LLP, one of the nation’s top 10 public accounting firms, to strengthen shareholder confidence in our financial reportingActively preparing for an uplist to the OTCQB within the next six months ASHLAND, Ky., Sept. 25, 2025 (GLOBE NEWSWIRE) -- TX Rail Products, Inc. (OTC Markets PINK: TXRP), a supplier of rail and rail products to the U.S. coal mining industry, short line ...

Hisense, Toshiba and other leading OEM native Smart TV inventory exclusively available for programmatic activation in Nexxen DSP, with further OEMs to participate in new marketplace Viewers spend up to ​10.5 minutes ​browsing content on their Smart TV home screens, creating windows of attention in a highly visible environment NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nexxen, a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced the first-to-market ...

MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- NioBay Metals Inc. ("NioBay" or the "Company") (TSX-V: NBY) (OTCQB: NBYCF) is proud to announce the appointment of the first members of its Technical Advisory Committee. This committee will assist the Board of Directors and management in the next phases of the Company's development. These first members represent fields as varied as academia, geology, metallurgy, and Indigenous relations, as well as knowledge of the niobium market. We believe that the addition of ...